The size for DTaP Vaccine Market was USD 3.26 Billion in 2020 and is projected to reach USD 5.51 Billion by 2028, with a Compound Annual Growth Rate (CAGR) of 6.84% during the forecast period. The growth of the DTaP vaccine market is anticipated to be fueled by the introduction of combination vaccines recommended for immunization programs. These vaccines aim to reduce the number of injections required while ensuring compliance with immunization in infants. The DTaP vaccine addresses three diseases—diphtheria, tetanus, and pertussis.

In 2017, the demand for vaccines containing D&T reached 945 million doses. By 2018, approximately 86% of infants worldwide received three doses of the DTP3 (diphtheria-tetanus-pertussis 3) vaccine, providing protection against infectious diseases that could lead to severe illness and disability in adulthood. Despite this progress, there were still 151,000 registered cases of pertussis globally in 2018.

Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/1284

Competitive landscape:            

The companies profiled in the report are GlaxoSmithKline, Sanofi Pasteur, Protein Sciences Corporation, Novartis AG, Merch Sharp & Dohme Corp., Pfizer Inc., Astellas Pharma US, Sanofi Aventis, AstraZeneca, and Emergent Biosolution Inc. These industry players are focusing on developing combination vaccines to lower disease burden globally.

To know more about the report @ https://www.reportsanddata.com/report-detail/dtap-vaccine-market

Driving Factors Of Dtap Vaccine Market

1. Introduction of Combination Vaccines: The DTaP vaccine market is driven by the introduction of combination vaccines, which are recommended for immunization programs. These vaccines help reduce the number of injections required, enhancing convenience and compliance.
2. Immunization Programs: The demand for DTaP vaccines is influenced by widespread immunization programs aimed at protecting infants from diseases such as diphtheria, tetanus, and pertussis. These programs contribute to the overall growth of the DTaP vaccine market.
3. Comprehensive Disease Coverage: The DTaP vaccine targets three diseases simultaneously—diphtheria, tetanus, and pertussis—providing a comprehensive solution for disease prevention. This broad coverage is a significant factor driving the market's adoption.
4. Global Vaccination Initiatives: Initiatives and campaigns at a global level to increase vaccination coverage, especially among infants, contribute to the growth of the DTaP vaccine market. These initiatives aim to improve overall public health.

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1284

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370a

E-mail: sales@reportsanddata.com

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @ https://www.reportsanddata.com/report